1.Successful cholecalciferol desensitisation in a case of delayed hypersensitivity
Anthea ANANTHARAJAH ; Anthony LAMPROGLOU ; Sylvia BRIDLE ; Weiwen CHEN ; Winnie TONG
Asia Pacific Allergy 2019;9(2):e14-
Hypersensitivity to cholecalciferol (vitamin D3) or its active metabolite, calcitriol, is an exceedingly rare clinical phenomenon, with only 2 previously reported cases of suspected immediate hypersensitivity. Diagnosis of delayed drug hypersensitivity reactions is inherently difficult due to the lack of any robust in vitro diagnostic assay, particularly in those patients for whom provocation testing confers an unacceptable risk. In these situations, diagnosis relies on reproducible clinical manifestations following administration of the culprit agent, resolution upon its withdrawal and exclusion of other potential differential diagnoses. Based on these criteria, we propose the first reported case of delayed hypersensitivity to cholecalciferol successfully managed with a desensitisation protocol to pure cholecalciferol.
Calcitriol
;
Cholecalciferol
;
Diagnosis
;
Diagnosis, Differential
;
Drug Hypersensitivity
;
Humans
;
Hypersensitivity
;
Hypersensitivity, Delayed
;
Hypersensitivity, Immediate
;
In Vitro Techniques
2.Does Acupuncture Therapy Alter Activation of Neural Pathway for Pain Perception in Irritable Bowel Syndrome?: A Comparative Study of True and Sham Acupuncture Using Functional Magnetic Resonance Imaging.
Winnie C W CHU ; Justin C Y WU ; David T W YEW ; Liang ZHANG ; Lin SHI ; David K W YEUNG ; Defeng WANG ; Raymond K Y TONG ; Yawen CHAN ; Lixing LAO ; Ping C LEUNG ; Brian M BERMAN ; Joseph J Y SUNG
Journal of Neurogastroenterology and Motility 2012;18(3):305-316
BACKGROUND/AIMS: Patients with irritable bowel syndrome (IBS) are characterized by abnormal central processing with altered brain activation in response to visceral nociceptive signals. The effect of electroacupuncture (EA) on IBS patients is unclear. The study is set to study the effect of EA on brain activation during noxious rectal distension in IBS patients using a randomized sham-controlled model. METHODS: Thirty IBS-diarrhea patients were randomized to true electroacupuncture or sham acupuncture. Functional MRI was performed to evaluate cerebral activation at the following time points: (1) baseline when there was rectal distension only, (2) rectal distension during application of EA, (3) rectal distension after cessation of EA and (4) EA alone with no rectal distension. Group comparison was made under each condition using SPM5 program. RESULTS: Rectal distension induced significant activation of the anterior cingulated cortex, prefrontal cortex, thalamus, temporal regions and cerebellum at baseline. During and immediately after EA, increased cerebral activation from baseline was observed in the anterior cingulated cortex, bilateral prefrontal cortex, thalamus, temporal regions and right insula in both groups. However, true electroacupuncture led to significantly higher activation at right insula, as well as pulvinar and medial nucleus of the thalamus when compared to sham acupuncture. CONCLUSIONS: We postulate that acupuncture might have the potential effect of pain modulation in IBS by 2 actions: (1) modulation of serotonin pathway at insula and (2) modulation of mood and affection in higher cortical center via ascending pathway at the pulvinar and medial nucleus of the thalamus.
Acupuncture
;
Acupuncture Therapy
;
Brain
;
Cerebellum
;
Electroacupuncture
;
Humans
;
Irritable Bowel Syndrome
;
Magnetic Resonance Imaging
;
Magnetic Resonance Spectroscopy
;
Magnetics
;
Magnets
;
Neural Pathways
;
Pain Perception
;
Prefrontal Cortex
;
Pulvinar
;
Salicylamides
;
Serotonin
;
Thalamus
3.High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves' Disease.
Wei Lin TAY ; Chiaw Ling CHNG ; Carolyn Sy TIEN ; Kelvin Sh LOKE ; Winnie Wc LAM ; Stephanie Mc FOOK-CHONG ; Aaron Kt TONG
Annals of the Academy of Medicine, Singapore 2019;48(6):181-187
INTRODUCTION:
Our study aimed to identify the factors associated with successful first-time radioactive iodine (RAI) treatment in patients with Graves' disease (GD).
MATERIALS AND METHODS:
This is a restrospective study of patients with GD who were treated with RAI. Treatment success was defined as onset of permanent hypothyroidism or euthyroidism after 1 dose of RAI at 1-year follow-up.
RESULTS:
There were 388 GD patients who underwent RAI treatment between January 2014 and December 2015. Of these, 74% achieved treatment success. Median time to achieve permanent hypothyroidism was 2 months. Male gender, smoking, higher antithyroid drug dosage, lower thyroid stimulating hormone (TSH) level, large goitre size and TSH receptor antibody (TRAb) titre at time of RAI were significantly associated with treatment failure. Multivariate analysis showed that larger goitre size and higher TRAb titre were associated with lower first-time RAI success.
CONCLUSION
Larger goitre size and higher TRAb titre predict lower success of RAI therapy in GD patients. Treatment decisions and strategies should be customised for patients who present with these characteristics.
4.Current Status and Growth of Nuclear Theranostics in Singapore
Hian Liang HUANG ; Aaron Kian Ti TONG ; Sue Ping THANG ; Sean Xuexian YAN ; Winnie Wing Chuen LAM ; Kelvin Siu Hoong LOKE ; Charlene Yu Lin TANG ; Lenith Tai Jit CHENG ; Gideon Su Kai OOI ; Han Chung LOW ; Butch Maulion MAGSOMBOL ; Wei Ying THAM ; Charles Xian Yang GOH ; Colin Jingxian TAN ; Yiu Ming KHOR ; Sumbul ZAHEER ; Pushan BHARADWAJ ; Wanying XIE ; David Chee Eng NG
Nuclear Medicine and Molecular Imaging 2019;53(2):96-101
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
Hope
;
Humans
;
Lutetium
;
Membranes
;
Nuclear Medicine
;
Prostate
;
Radium
;
Receptors, Peptide
;
Singapore
;
Theranostic Nanomedicine
;
Yttrium
5.Current Status and Growth of Nuclear Theranostics in Singapore
Hian Liang HUANG ; Aaron Kian Ti TONG ; Sue Ping THANG ; Sean Xuexian YAN ; Winnie Wing Chuen LAM ; Kelvin Siu Hoong LOKE ; Charlene Yu Lin TANG ; Lenith Tai Jit CHENG ; Gideon Su Kai OOI ; Han Chung LOW ; Butch Maulion MAGSOMBOL ; Wei Ying THAM ; Charles Xian Yang GOH ; Colin Jingxian TAN ; Yiu Ming KHOR ; Sumbul ZAHEER ; Pushan BHARADWAJ ; Wanying XIE ; David Chee Eng NG
Nuclear Medicine and Molecular Imaging 2019;53(2):96-101
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.
6.A summary of the Malaysian Clinical Practice Guidelines on the management of postmenopausal osteoporosis, 2022
Terence Ing WEI ONG ; Lee Ling LIM ; Siew Pheng CHAN ; Winnie Siew SWEE CHEE ; Alan Swee HOCK CH’NG ; Elizabeth GAR MIT CHONG ; Premitha DAMODARAN ; Fen Lee HEW ; Luqman bin IBRAHIM ; Hui Min KHOR ; Pauline Siew MEI LAI ; Joon Kiong LEE ; Ai Lee LIM ; Boon Ping LIM ; Sharmila Sunita PARAMASIVAM ; Jeyakantha RATNASINGAM ; Yew Siong SIOW ; Alexander Tong BOON TAN ; Nagammai THIAGARAJAN ; Swan Sim YEAP
Osteoporosis and Sarcopenia 2023;9(2):60-69
Objectives:
The aim of these Clinical Practice Guidelines is to provide evidence-based recommendations to assist healthcare providers in the screening, diagnosis and management of patients with postmenopausal osteoporosis (OP).
Methods:
A list of key clinical questions on the assessment, diagnosis and treatment of OP was formulated. A literature search using the PubMed, Medline, Cochrane Databases of Systematic Reviews, and OVID electronic databases identified all relevant articles on OP based on the key clinical questions, from 2014 onwards, to update from the 2015 edition. The articles were graded using the SIGN50 format. For each statement, studies with the highest level of evidence were used to frame the recommendation.
Results:
This article summarizes the diagnostic and treatment pathways for postmenopausal OP. Risk stratification of patients with OP encompasses clinical risk factors, bone mineral density measurements and FRAX risk estimates. Non-pharmacological measures including adequate calcium and vitamin D, regular exercise and falls prevention are recommended. Pharmacological measures depend on patients’ fracture risk status. Very high-risk individuals are recommended for treatment with an anabolic agent, if available, followed by an anti-resorptive agent. Alternatively, parenteral anti-resorptive agents can be used. High-risk individuals should be treated with anti-resorptive agents. In low-risk individuals, menopausal hormone replacement or selective estrogen receptor modulators can be used, if indicated. Patients should be assessed regularly to monitor treatment response and treatment adjusted, as appropriate.
Conclusions
The pathways for the management of postmenopausal OP in Malaysia have been updated. Incorporation of fracture risk stratification can guide appropriate treatment.